[1] KHOSLA S，WESTENDORF J J，OURSLER M J. Building bone to reverse osteoporosis and repair fractures[J]. J Clin Invest，2008，118(2：421-428.
[2] SUBBIAH V，MADSEN V S，RAYMOND A K，et al. Of mice and men： divergent risks of teriparatide-induced osteosarcoma [J]. Osteoporos Int，2010，21(6：1041-1045.
[3] GLASS D A，KARSENTY G. In vivo analysis of Wnt signaling in bone[J]. Endocrinology，2007，148(6： 2630-2634.
[4] KENNELL J A，MACHOUGALD O A. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms[J]. J Biol Chem，2005，280(25： 24004-24010.
[5] BENNETT C N，LONGO K A，WRIGHT W S，et al. Regulation of osteoblastogenesis and bone mass by Wnt10b[J]. Proc Natl Acad Sci USA，2005，102(9： 3324-3329.
[6] LONGO K A，WRIGHT W S，KANG S，et al. Wnt10b inhibits development of white and brown adipose tissues[J]. J Biol Chem，2004，279(34： 35503-35509.
[7] ROSS S E，HEMATI N，LONGO K A，et al. Inhibition of adipogenesis by Wnt signaling[J]. Science，2000， 289(5481： 950-953.
[8] MBALAVIELE G，SHEIKH S，STAINS J P，et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation[J]. J Cell Biochem，2005，94(2： 403-418.
[9] GLASS D A 2ND，BIALEK P，AHN J D，et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation[J]. Dev Cell，2005，8(5： 751-764.
[10] VANDER HORST G，VANDERWERF S M，FARIH-SIPS H，et al. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells[J]. J Bone Miner Res，2005，20(10： 1867-1877.
[11] SEMENOV M V，HE X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST[J]. J Biol Chem，2006，281(50： 38276-38284.
[12] ELLIES D L，VIVIANO B，MCCARTHY J，et al. Bone density ligand Sclerostin.directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity[J]. J Bone Miner Res，2006，21(11： 1738-1749.
[13] HENRIKSEN K，GRAM J，HOEGH-ANDERSEN P，et al. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro，but have decreased resorption capacity in vivo[J]. Am J Pathol，2005，167(5： 1341-1348.
[14] HOLMEN S L，GIAMBERNARDI T A，ZYLSTRA C R，et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6[J]. J Bone Miner Res，2004，19(12： 2033-2040.
[15] MANI A，RADHAKRISHNAN J，WANG H，et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors[J]. Science，2007，315(5816： 1278-1282.
[16] WAN M，YANG C，LI J，et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6[J]. Genes Dev，2008，22(21： 2968-2979.
[17] YADAV V K，RYU J H，SUNDA N，et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum[J]. Cell，2008，135(5： 825-837.
[18] KULKARNI N H，ONYIA J E，ZENG Q，et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo[J]. J Bone Miner Res， 2006，21(6：910-920.
[19] GARDNER J C，VANBEZOOIJEN R L，MERVIS B，et al. Bone mineral density in sclerosteosis； affected individuals and gene carriers[J]. J Clin Endocrinol Metab，2005，90(12： 6392-6395.
[20] REPPE S，REFVEM H，GAUTVIK V T，et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women[J]. Bone，2010，46(3：604-612.
[21] LIN C，JIANG X，DAI Z，et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling[J]. J Bone Miner Res，2009，24(10：1651-1661.
[22] AI M，HOLMEN S L，VANHUL W，et al. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling[J]. Mol Cell Biol，2005，25(12： 4946-4955.
[23] DAVIDSON G，MAO B，DELBARCO B I，et al. Kremen proteins interact with Dickkopf1 to regulate anteroposterior CNS patterning[J]. Development，2002，129(24： 5587-5596.
[24] ELLWANGER K，SAITO H，CLEMENT L P，et al. Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density[J]. Mol Cell Biol，2008，28(15： 4875-4882.
[25] SEMENOV M V，ZHANG X，HE X. DKK1 antagonizes Wnt signaling without promotion of LRP6 internalization and degradation[J]. J Biol Chem，2008，283(31： 21427-21432.
[26] WANG K，ZHANG Y，LI X，et al. Characterization of the Kremen-binding site on Dkk1 and elucidation of the role of Kremen in Dkk-mediated Wnt antagonism[J]. J Biol Chem，2008，283(34： 23371-23375.
[27] CAO J J，SINGLETON P A，MAJUMDAR S，et al. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44[J]. J Bone Miner Res，2005，20(1： 30-40.
[28] LI X，LIU P，LIU W，et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation[J]. Nat Genet，2005，37(9： 945-952.
[29] BODINE P V，STAUFFER B，PONCEDELEON H，et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation[J]. Bone，2009，44(6：1063-1068.
[30] BOVOLENTA P，ESTEVE P，RUIZ J M，et al. Beyond Wnt inhibition： new functions of secreted Frizzled-related proteins in development and disease[J]. J Cell Sci，2008，121(Pt 6：737-746.